Category - New Drugs
Sarclisa Approved in the US as the First Anti-CD38 Therapy in Combination with Standard-of-Care Treatment for Adult Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
FDA Approves Miplyffa (arimoclomol) for the Treatment of Niemann-Pick Disease Type C
FluMist Approved for Self-Administration in the US
Rybrevant (amivantamab-vmjw) Plus Standard of Care Approved in the U.S. as First and Only Targeted Regimen to Cut Risk of Disease Progression by More Than Half in Second-Line EGFR-Mutated Advanced Lung Cancer
FDA Approves Merck’s Keytruda (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis
FDA Approves Kisqali to Reduce Risk of Recurrence in People with HR+/HER2- Early Breast Cancer
FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis